Expedited pathway portfolios, trial complexity, and FDA approval timelines in oncology and neurology: A comparative analysis

Ahmed M Sayed, Nada M Ezzelarab, Nguyen Tien Huy · 2026

Read Expedited pathway portfolios, trial complexity, and FDA approval timelines in oncology and neurology: A comparative analysis by Ahmed M Sayed, Nada M Ezzelarab, Nguyen Tien Huy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0355495.txt.

Description

Ahmed M Sayed, Nada M Ezzelarab, and Nguyen Tien Huy compared how cancer and neurology drugs move through United States approval. They asked whether speed comes from stacking fast-track perks or from trial design. Their 2026 study reviewed nearly two hundred original approvals from 2015 to 2024. It scored each drug's bundle of expedited designations. It then examined the trials behind each approval.

Cancer drugs collected more expedited perks. They cleared regulatory review months faster than neurology drugs. Yet total time from development start to approval barely differed. Neurology trials were more often randomized, blinded, and late-stage. Cancer trials often used single groups. The contrast suggests review speed reflects the evidence package regulators accept, not just the perks a sponsor collects.

Catalog record

CREATORAhmed M Sayed, Nada M Ezzelarab, Nguyen Tien Huy
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39900
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0355495

Browse the full library · About the Tower of Babel